Treatment of the antiphospholipid syndrome

Galli, Mónica

doi:10.1007/s13317-013-0056-5

Cited by 17 publications

(8 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In some patients, treatment with anticoagulation or antiplatelets improved symptoms [8]. However, it remains controversial whether aspirin is adequate as a prophylactic 2 Case Reports in Rheumatology agent [9], although the patient states that aspirin has been relieving her symptoms. If symptoms persist or return, the use of IVIG to treat antiphospholipid syndrome can be considered [10].…”

Section: Discussionmentioning

confidence: 99%

POTS and Antiphospholipid Syndrome: An Unlikely Association

Zee

Qureshi

2021

Case Reports in Rheumatology

View full text Add to dashboard Cite

Antiphospholipid syndrome is a rare complication of postural orthostatic tachycardia syndrome. Clinically, the presentation has overlapping symptoms of both diseases, with lightheadedness or syncope when moving from a supine to a standing position as well as blood clots, headache, or pregnancy complications in women. This case presentation involves a 39-year-old patient identified as female who has been diagnosed with POTS and elevated anticardiolipin antibodies.

show abstract

Section: Discussionmentioning

confidence: 99%

POTS and Antiphospholipid Syndrome: An Unlikely Association

Zee

Qureshi

2021

Case Reports in Rheumatology

View full text Add to dashboard Cite

show abstract

“…There is no second line therapy for women with adverse pregnancy outcomes despite antithrombotic therapy. [11] Liver dysfunction with abnormal liver tests in pregnancy represents 3% of the deliveries. The cardinal features of hepatobiliary disease can include jaundice, pruritus, abdominal pain, nausea, vomiting, and a variety of liver biochemical test abnormalities.…”

Section: Discussionmentioning

confidence: 99%

Hepatic infarction in a pregnant woman with antiphospholipid syndrome and early pre-eclampsia: A case report

Ntovas

Moles

Papadatou

et al. 2020

CRIM

View full text Add to dashboard Cite

The aim of the present case report is to stress out the occurrence of hepatic infraction in pregnant women with antiphospholipid syndrome (APS) and the critical role magnetic resonance imaging (MRI) plays for the early diagnosis of rare complications of the disease. Here we report the case of a preeclamptic pregnant woman with APS in her 17th week of gestation, who experienced severe epigastric pain, followed by multiple episodes of vomiting and an episode of soft stools. Patient was submitted to MRI examination of the upper abdomen, where findings suggested hepatic infarction with subsequent deterioration of her general status. Therefore, she underwent termination of gestation. We conclude that pregnancy is a deteriorating factor of the disease and patient should be closely monitored, evaluated of any suspicious symptom or sign.

show abstract

“…The lack of strong evidence-based data for antithrombotic strategies in asymptomatic aPL carriers is still an open issue. Consequently, recommendations are mainly based on low-quality studies and expert opinions [ 20 , 59 ].…”

Section: Prevention Strategies In Apl Carriersmentioning

confidence: 99%

Risk Assessment and Antithrombotic Strategies in Antiphospholipid Antibody Carriers

et al. 2021

View full text Add to dashboard Cite

Antiphospholipid antibodies (aPL) are a cluster of autoantibodies directed against plasma proteins with affinity for membrane phospholipids. The most frequently tested aPL are lupus anticoagulant (LA), anti-cardiolipin antibodies (aCL), and anti-β2-glycoprotein I antibodies (anti-β2GPI). aPL play a key pathogenic role in the development of the antiphospholipid syndrome (APS), a systemic autoimmune disease characterized by recurrent thrombotic and/or pregnancy complications in patients with persistent aPL. However, aPL positivity is occasionally documented in patients with no previous history of thrombotic or pregnancy morbidity. LA activity, multiple aPL positivity, high-titer aPL, and a concomitant systemic autoimmune disease are recognized risk factors for future thrombotic events in asymptomatic carriers. Moreover, an accelerated atherosclerosis with increased cardiovascular (CV) risk has also been associated with aPL positivity, thus exposing aPL carriers to fatal complications and chronic disability requiring cardiac rehabilitation. Overall, an accurate risk stratification is recommended for aPL-positive subjects in order to prevent both venous and arterial thrombotic complications. In this review, we provide an overview of the main antithrombotic and risk assessment strategies in aPL carriers.

show abstract

Treatment of the antiphospholipid syndrome

Cited by 17 publications

References 71 publications

POTS and Antiphospholipid Syndrome: An Unlikely Association

POTS and Antiphospholipid Syndrome: An Unlikely Association

Hepatic infarction in a pregnant woman with antiphospholipid syndrome and early pre-eclampsia: A case report

Risk Assessment and Antithrombotic Strategies in Antiphospholipid Antibody Carriers

Contact Info

Product

Resources

About